Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial
Background/aims To evaluate the efficacy, safety and tolerability of enteric-coated mycophenolate sodium (EC-MPS) in combination with low-dose corticosteroids compared with a monotherapy with low-dose corticosteroids in subjects with non-infectious intermediate uveitis (IU).Methods Open-label, pro...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
British journal of ophthalmology
Year: 2017, Jahrgang: 102, Heft: 5, Pages: 647-653 |
| ISSN: | 1468-2079 |
| DOI: | 10.1136/bjophthalmol-2017-310156 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1136/bjophthalmol-2017-310156 Verlag, Volltext: http://bjo.bmj.com/lookup/doi/10.1136/bjophthalmol-2017-310156 
|
| Verfasserangaben: | Christoph M E Deuter, Katrin Engelmann, Arnd Heiligenhaus, Ines Lanzl, Friederike Mackensen, Thomas Ness, Uwe Pleyer, Nicole Stuebiger, Barbara Wilhelm, Holger Luedtke, Manfred Zierhut, Deshka Doycheva |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1582168504 | ||
| 003 | DE-627 | ||
| 005 | 20230427193147.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181022r20182017xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bjophthalmol-2017-310156 |2 doi | |
| 035 | |a (DE-627)1582168504 | ||
| 035 | |a (DE-576)512168504 | ||
| 035 | |a (DE-599)BSZ512168504 | ||
| 035 | |a (OCoLC)1341020128 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Deuter, Christoph M.E. |d 1968- |e VerfasserIn |0 (DE-588)122088956 |0 (DE-627)705768104 |0 (DE-576)182571157 |4 aut | |
| 245 | 1 | 0 | |a Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis |b results of a prospective, controlled, randomised, open-label, early terminated multicentre trial |c Christoph M E Deuter, Katrin Engelmann, Arnd Heiligenhaus, Ines Lanzl, Friederike Mackensen, Thomas Ness, Uwe Pleyer, Nicole Stuebiger, Barbara Wilhelm, Holger Luedtke, Manfred Zierhut, Deshka Doycheva |
| 264 | 1 | |c 2018 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online first 13 September 2017 | ||
| 500 | |a Gesehen am 22.10.2018 | ||
| 520 | |a Background/aims To evaluate the efficacy, safety and tolerability of enteric-coated mycophenolate sodium (EC-MPS) in combination with low-dose corticosteroids compared with a monotherapy with low-dose corticosteroids in subjects with non-infectious intermediate uveitis (IU).Methods Open-label, prospective, controlled, randomised multicentre trial. Patients were randomised in a 1:1 ratio to either the treatment group (prednisolone plus EC-MPS) or control group (prednisolone monotherapy). Patients in the control group who relapsed within 6 months changed to the crossover group (prednisolone plus EC-MPS). Maximum treatment duration was 15 months. The primary endpoint was the time to first relapse in the treatment group and control group.Results Forty-one patients at eight sites were analysed. Twenty-two patients were allocated to the treatment group, with 19 patients in the control group. A first relapse occurred in 9 patients (40.9%) in the treatment group and 15 patients (78.9%) in the control group (p=0.03). The median time to the first relapse was >15 months for the treatment group and 2.8 months for the control group (p=0.07). The probability of relapse-free survival at month 15 was estimated to be 52.9% in the treatment group and 19.7% in the control group (p=0.01). 15 patients changed to the crossover group. Of these, only four patients developed a second relapse. No safety concerns arose during the trial. Only one patient had to discontinue EC-MPS due to increased liver enzymes.Conclusion EC-MPS can be considered an effective and well-tolerated immunosuppressive drug to prevent relapses in patients with chronic IU. Trial registration number EUDRACT number: 2009009998-10, Results. | ||
| 534 | |c 2017 | ||
| 700 | 1 | |a Mackensen, Friederike |d 1974-2016 |e VerfasserIn |0 (DE-588)123739594 |0 (DE-627)706412761 |0 (DE-576)29385386X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of ophthalmology |d London : BMJ Publ. Group, 1917 |g 102(2018), 5, Seite 647-653 |h Online-Ressource |w (DE-627)300594267 |w (DE-600)1482974-5 |w (DE-576)078993598 |x 1468-2079 |7 nnas |a Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis results of a prospective, controlled, randomised, open-label, early terminated multicentre trial |
| 773 | 1 | 8 | |g volume:102 |g year:2018 |g number:5 |g pages:647-653 |g extent:7 |a Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis results of a prospective, controlled, randomised, open-label, early terminated multicentre trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bjophthalmol-2017-310156 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://bjo.bmj.com/lookup/doi/10.1136/bjophthalmol-2017-310156 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181022 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 123739594 |a Mackensen, Friederike |m 123739594:Mackensen, Friederike |d 50000 |e 50000PM123739594 |k 0/50000/ |p 5 | ||
| 999 | |a KXP-PPN1582168504 |e 3029458601 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"2018"}],"id":{"eki":["1582168504"],"doi":["10.1136/bjophthalmol-2017-310156"]},"name":{"displayForm":["Christoph M E Deuter, Katrin Engelmann, Arnd Heiligenhaus, Ines Lanzl, Friederike Mackensen, Thomas Ness, Uwe Pleyer, Nicole Stuebiger, Barbara Wilhelm, Holger Luedtke, Manfred Zierhut, Deshka Doycheva"]},"physDesc":[{"extent":"7 S."}],"relHost":[{"disp":"Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis results of a prospective, controlled, randomised, open-label, early terminated multicentre trialBritish journal of ophthalmology","note":["Gesehen am 03.12.12"],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"300594267","language":["eng"],"corporate":[{"role":"isb","display":"University of London","roleDisplay":"Herausgebendes Organ"}],"pubHistory":["1.1917 -"],"titleAlt":[{"title":"BJO"}],"part":{"year":"2018","issue":"5","pages":"647-653","volume":"102","text":"102(2018), 5, Seite 647-653","extent":"7"},"title":[{"title_sort":"British journal of ophthalmology","subtitle":"BJO","title":"British journal of ophthalmology"}],"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["Institute of Ophthalmology. Ed. Sir Stewart Duke-Elder [u.a.]"]},"origin":[{"publisherPlace":"London","dateIssuedKey":"1917","publisher":"BMJ Publ. Group","dateIssuedDisp":"1917-"}],"id":{"eki":["300594267"],"zdb":["1482974-5"],"issn":["1468-2079"]}}],"title":[{"title_sort":"Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis","subtitle":"results of a prospective, controlled, randomised, open-label, early terminated multicentre trial","title":"Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis"}],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Deuter, Christoph M.E.","given":"Christoph M.E.","family":"Deuter"},{"role":"aut","display":"Mackensen, Friederike","roleDisplay":"VerfasserIn","given":"Friederike","family":"Mackensen"}],"note":["Published online first 13 September 2017","Gesehen am 22.10.2018"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1582168504","language":["eng"]} | ||
| SRT | |a DEUTERCHRIENTERICCOA2018 | ||